Business News

Haemonetics price target raised to $110 from $100 at Mizuho

AC Immune opens new centers in Phase 1b/2 ACI-24 trial in AD and Down Syndrome

Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics to $110 from $100 and keeps a Buy rating on the shares. The analyst updated medtech and diagnostics models ahead of the Q4 earnings season to reflect feedback from last week’s West Coast broker conference and ongoing hospital/physician channel checks. The general tone suggested the elevated respiratory viral volumes did not impact inpatient volumes, although some pockets of weakness did emerge in outpatient elective procedures, the analyst tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on HAE:

Click Here to Read the Full Original Article at TipRanks Financial Blog…